Cargando…

Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting

PURPOSE: To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). METHODS: A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Best, Anne-Laurence, Fajnkuchen, Franck, Nghiem-Buffet, Sylvia, Grenet, Typhaine, Quentel, Gabriel, Delahaye-Mazza, Corinne, Cohen, Salomon Y., Giocanti-Aurégan, Audrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932481/
https://www.ncbi.nlm.nih.gov/pubmed/29850205
http://dx.doi.org/10.1155/2018/4610129
_version_ 1783319825471242240
author Best, Anne-Laurence
Fajnkuchen, Franck
Nghiem-Buffet, Sylvia
Grenet, Typhaine
Quentel, Gabriel
Delahaye-Mazza, Corinne
Cohen, Salomon Y.
Giocanti-Aurégan, Audrey
author_facet Best, Anne-Laurence
Fajnkuchen, Franck
Nghiem-Buffet, Sylvia
Grenet, Typhaine
Quentel, Gabriel
Delahaye-Mazza, Corinne
Cohen, Salomon Y.
Giocanti-Aurégan, Audrey
author_sort Best, Anne-Laurence
collection PubMed
description PURPOSE: To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). METHODS: A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. RESULTS: Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p < 0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p = 0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n = 55). DISCUSSION/CONCLUSION: Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients.
format Online
Article
Text
id pubmed-5932481
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59324812018-05-30 Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting Best, Anne-Laurence Fajnkuchen, Franck Nghiem-Buffet, Sylvia Grenet, Typhaine Quentel, Gabriel Delahaye-Mazza, Corinne Cohen, Salomon Y. Giocanti-Aurégan, Audrey J Ophthalmol Research Article PURPOSE: To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). METHODS: A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. RESULTS: Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p < 0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p = 0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n = 55). DISCUSSION/CONCLUSION: Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. Hindawi 2018-04-18 /pmc/articles/PMC5932481/ /pubmed/29850205 http://dx.doi.org/10.1155/2018/4610129 Text en Copyright © 2018 Anne-Laurence Best et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Best, Anne-Laurence
Fajnkuchen, Franck
Nghiem-Buffet, Sylvia
Grenet, Typhaine
Quentel, Gabriel
Delahaye-Mazza, Corinne
Cohen, Salomon Y.
Giocanti-Aurégan, Audrey
Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
title Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
title_full Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
title_fullStr Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
title_full_unstemmed Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
title_short Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
title_sort treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932481/
https://www.ncbi.nlm.nih.gov/pubmed/29850205
http://dx.doi.org/10.1155/2018/4610129
work_keys_str_mv AT bestannelaurence treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting
AT fajnkuchenfranck treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting
AT nghiembuffetsylvia treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting
AT grenettyphaine treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting
AT quentelgabriel treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting
AT delahayemazzacorinne treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting
AT cohensalomony treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting
AT giocantiaureganaudrey treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting